• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Arcus Biosciences Inc (NY: RCUS )

    15.49 +0.08 (+0.52%)
    Streaming Delayed Price Updated: 11:12 AM EDT, Sep 30, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 190,337
    Open 15.36
    Bid (Size) 15.48 (2)
    Ask (Size) 15.51 (5)
    Prev. Close 15.41
    Today's Range 15.31 - 15.76
    52wk Range 12.95 - 20.31
    Shares Outstanding 91,300,000
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Arcus Biosciences Announces New Employment Inducement Grants
    From Arcus Biosciences
    Via Business Wire
    Arcus Biosciences Announces New Employment Inducement Grants
    From Arcus Biosciences
    Via Business Wire

    Performance

    YTD
    -21.29%
    -21.29%
    1 Month
    -9.52%
    -9.52%
    3 Month
    +1.24%
    +1.24%
    6 Month
    -16.18%
    -16.18%
    1 Year
    -10.41%
    -10.41%

    More News

    Read More
    Arcus Biosciences Secures Up to $250 Million Term Loan Facility from Hercules Capital
    From Arcus Biosciences
    Via Business Wire
    Breaking Down Arcus Biosciences: 4 Analysts Share Their Views
    Via Benzinga
    Cracking The Code: Understanding Analyst Reviews For Arcus Biosciences
    Via Benzinga
    Arcus Biosciences Announces New Employment Inducement Grants
    From Arcus Biosciences
    Via Business Wire
    Arcus Biosciences to Participate in Two Upcoming Investor Conferences
    From Arcus Biosciences
    Via Business Wire
    RCUS Stock Earnings: Arcus Biosciences Beats EPS, Beats Revenue for Q2 2024
    Via InvestorPlace
    Arcus Biosciences Reports Second-Quarter 2024 Financial Results and Provides a Pipeline Update
    From Arcus Biosciences
    Via Business Wire
    Sagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of Directors
    From Sagimet Biosciences Inc.
    Via GlobeNewswire
    Arcus Biosciences to Host Conference Call to Discuss Second-Quarter 2024 Financial Results and Pipeline Update
    From Arcus Biosciences
    Via Business Wire
    Arcus Biosciences Announces New Employment Inducement Grants
    From Arcus Biosciences
    Via Business Wire
    Taiho Pharmaceutical Exercises Option for an Exclusive License to Quemliclustat in Japan and Certain Territories in Asia
    From Arcus Biosciences
    Via Business Wire
    Arcus Biosciences Announces New Employment Inducement Grants
    From Arcus Biosciences
    Via Business Wire
    Arcus Biosciences Announces New Employment Inducement Grants
    From Arcus Biosciences
    Via Business Wire
    Arcus Biosciences Completes Patient Enrollment in Phase 3 Trial Evaluating a Domvanalimab-Containing Regimen in First-Line Metastatic Upper GI Cancers
    From Arcus Biosciences
    Via Business Wire
    Arcus Biosciences to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
    From Arcus Biosciences
    Via Business Wire
    After Disappointing Bladder Cancer Data, Gilead Announces Encouraging Data From Gastric, Colorectal Cancer Studies
    Via Benzinga
    Gilead and Arcus Announce Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-line Metastatic Colorectal Cancer
    From Gilead Sciences, Inc.
    Via Business Wire
    Gilead and Arcus Announce Anti-TIGIT Domvanalimab Plus Zimberelimab and Chemotherapy Exceeded One Year of Median Progression-Free Survival as a First-Line Treatment for Upper GI Cancers
    From Gilead Sciences, Inc.
    Via Business Wire
    Arcus Biosciences Announces New Employment Inducement Grants
    From Arcus Biosciences
    Via Business Wire
    12 Health Care Stocks Moving In Friday's Pre-Market Session
    Via Benzinga
    Arcus Biosciences Announces New Employment Inducement Grants
    From Arcus Biosciences
    Via Business Wire
    RCUS Stock Earnings: Arcus Biosciences Beats EPS, Beats Revenue for Q1 2024
    Via InvestorPlace
    Arcus Biosciences Reports First-Quarter 2024 Financial Results and Provides a Pipeline Update
    From Arcus Biosciences
    Via Business Wire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.